Background -The aim ofthis study was to determine whether significant differences exist in lung bioavailability between generic (Salamol, Salbulin) and innovator (Ventolin) formulations of inhaled salbutamol given by metered dose inhalers. Methods -Ten healthy volunteers of mean age 20-5 years with a forced expiratory volume in one second (FEV,) The subjects were studied on three days each separated by one week. They were instructed to inhale slowly from residual volume with breath holding for 10 seconds, and the technique was checked with an airways inhalation monitor (Vitalograph Ltd, Buckingham, UK) at each visit. Heart rate, tremor and potassium were measured at baseline and after 20 minutes.
inhalers."2 In contrast to the normal procedure for oral medications, the Medicines Control Agency only required in vitro testing for inhaled forms of generic salbutamol before licensing. We report on an in vivo study of the lung bioavailability of generic and innovator salbutamol metered dose inhalers. A pharmacokinetic evaluation oflung bioavailability was performed using measurement of plasma salbutamol concentration. 34 Comparison was made between the measurement of lung bioavailability using plasma and a method using 30 minute urinary excretion of salbutamol.5 In addition, the pharmacodynamic effects in terms of extrapulmonary 2 activity were also evaluated. heart rate was measured from standard lead II of an electrocardiogram monitor, and plasma potassium levels were assayed by flame photometry using an IL943 analyser (Instrumentation Laboratory Ltd, Warrington, UK). The intra-assay and interassay values for analytical imprecision were 0-41% and 1-04%, respectively. Plasma and urinary salbutamol levels were assayed by high performance liquid chromatography (HPLC) with solid phase extraction and fluorescence detection as previously described.7 The analytical imprecision for plasma salbutamol was 3 9% (intra-assay) and 4 1% (interassay) at 4 ng/ml, and 11 8% (intra-assay) and 12-6% (interassay) at 2 ng/ml; and for urinary salbutamol was 3-6% (intraassay) and 7-2% (interassay). The HPLC detection limit for salbutamol was 1 ng/ml.
DATA ANALYSIS
The results were analysed using the Statgraphics statistical software package (STSC Software Publishing Group, Rockville, Maryland, USA). Comparisons for all parameters were made by multifactorial analysis ofvariance (MANOVA) and Duncan's multiple range testing using subjects and treatments as within factors for the analysis. A probability value of p<0 05 (two tailed) was considered significant.
Results
No significant differences were seen between innovator and generic salbutamol metered dose We found no significant differences in either plasma or urine pharmacokinetic parameters of lung bioavailability between the innovator 5 to 66 6) and generic formulations. Likewise, all of the calculated dose ratios included unity, again 4 to 67 5) suggesting that there were no differences. We in; Tmax=time to only tested two generic formulations of salbutamol and hence we are unable to deduce any conclusions with respect to substituting other generic metered dose inhalers. Previous in vivo studies have investigated primarily the -----------~bronchodilator responses to generic and innovator salbutamol in asthmatic subjects and have not attempted to correlate this with lung bioavailability.8'" The urinary salbutamol excretion method has shown that a generic salbutamol metered dose inhaler can be used in 
